Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset FST-100, if approved, would be the first to treat both bacterial and viral eye infections, transforming treatment of acute conjunctivitis PR Newswire LEXINGTON, Massachusetts, August 3, 2015 LEXINGTON, Massachusetts , August 3, 2015 /PRNewswire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that it has acquired New York -based, privately held Foresight Biotherapeutics Inc. for $300 million . With the acquisition, Shire acquires the global rights to FST-100 (topical ophthalmic drops combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye. […]